Αποτελέσματα Αναζήτησης
The hormone oestrogen can encourage some breast cancer to develop and grow. Tamoxifen is an anti-oestrogen drug. It stops oestrogen attaching to breast cancer cells and making them grow. It only works for breast cancer that is oestrogen receptor positive (ER positive).
Hot flashes, night sweats, and vaginal dryness are common side effects of all hormone therapies. Hormone therapy also may disrupt the menstrual cycle in premenopausal women. Less common but serious side effects of hormone therapy drugs are listed below. Tamoxifen. risk of blood clots, especially in the lungs and legs; stroke; cataracts
Occasional side effects. These side effects happen in between 1 and 10 out of every 100 people (between 1 and 10%). You might have one or more of them. They include. leg cramps; hair thinning or hair loss; feeling light headed; eye problems, such as blurred vision, due to damage of the retina or cataracts.
20 Ιαν 2023 · Risk for tamoxifen adverse effects (stroke, cataracts, uterine cancer, etc.). Is it safe to take tamoxifen during pregnancy? Tamoxifen may cause birth defects. You shouldn’t take the medication if you’re pregnant or planning to become pregnant. To prevent pregnancy, talk to your healthcare provider about nonhormonal birth control options ...
8 Δεκ 2022 · This topic review will cover management of the major side effects of tamoxifen and AIs. The use of these agents as hormonal treatment for breast cancer, both in the adjuvant setting and for advanced disease, and their use as chemopreventive agents in women at increased risk for breast cancer are discussed elsewhere.
This booklet explains what tamoxifen is, when it may be prescribed, how it works and what side effects may occur. WHAT IS TAMOXIFEN? Tamoxifen is a drug used to treat breast cancer in both premenopausal women (women who have not yet gone through the menopause) and postmenopausal women. It can also be taken by men who have breast cancer.
10 Απρ 2023 · Tamoxifen use should be avoided in pregnancy; based on limited human data, the risk of teratogenicity and fetal harm exists. Women should avoid breastfeeding during treatment and for three months following discontinuing therapy due to the risk of infant harm.
